Cargando…

EGFR inhibition in EGFR‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR‐mutant non–small‐cell lung cancer (NSCLC) cells. However, little is known about the mechanisms through which these drugs alter the tumor phenotype that contributes to the immune escape o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiiya, Akihiko, Noguchi, Takuro, Tomaru, Utano, Ariga, Shin, Takashima, Yuta, Ohhara, Yoshihito, Taguchi, Jun, Takeuchi, Satoshi, Shimizu, Yasushi, Kinoshita, Ichiro, Koizumi, Tomonobu, Matsuno, Yoshihiro, Shinagawa, Naofumi, Sakakibara‐Konishi, Jun, Dosaka‐Akita, Hirotoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067399/ https://www.ncbi.nlm.nih.gov/pubmed/36529523 http://dx.doi.org/10.1111/cas.15701

Ejemplares similares

Early prediction of treatment outcome for lenvatinib using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
por: Takeuchi, Satoshi, et al.
Publicado: (2023)

Expression of Karyopherin Alpha 2 and Karyopherin Beta 1 Correlate with Poor Prognosis in Gastric Cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2022)

Role of targeted therapy in metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2016)

Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR ‐mutated non–small‐cell lung cancer
por: Takahashi, Hirofumi, et al.
Publicado: (2022)

DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail
por: Furuta, Megumi, et al.
Publicado: (2019)

Early prediction of lenvatinib treatment efficacy by using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study
por: Takeuchi, Satoshi, et al.
Publicado: (2018)

Late Onset of Non-islet Cell Tumor Hypoglycemia Managed via Multidisciplinary Treatment in a Patient with a Solitary Fibrous Tumor
por: Takeuchi, Satoshi, et al.
Publicado: (2018)

Expression of Bim, Noxa, and Puma in non-small cell lung cancer
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2012)

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells
por: Takashina, Taichi, et al.
Publicado: (2016)

Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners
por: Katabami, Motoo, et al.
Publicado: (2023)

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
por: Takeuchi, Satoshi, et al.
Publicado: (2011)

A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure
por: Ito, Shotaro, et al.
Publicado: (2021)

Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma
por: Kikuchi, Hajime, et al.
Publicado: (2018)

Assessment of early changes in (3)H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression
por: Zhao, Songji, et al.
Publicado: (2013)

Clinicopathological significance of expression of p-c-Jun, TCF4 and beta-Catenin in colorectal tumors
por: Takeda, Kayoko, et al.
Publicado: (2008)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Autophagy-dependent regulation of tumor metastasis by myeloid cells
por: Jinushi, Masahisa, et al.
Publicado: (2017)

Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers
por: Hagio, Kanako, et al.
Publicado: (2023)

Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology
por: Hirayama, Yasuo, et al.
Publicado: (2016)

Novel Process of Intrathymic Tumor-Immune Tolerance through CCR2-Mediated Recruitment of Sirpα(+) Dendritic Cells: A Murine Model
por: Baba, Tomohisa, et al.
Publicado: (2012)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

Risk of bleeding associated with transbronchial biopsy using flexible bronchoscopy in patients with echocardiographic or chest CT evidence of pulmonary hypertension
por: Takashima, Yuta, et al.
Publicado: (2022)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Elevated serum CYFRA 21‐1 level as a diagnostic marker for thymic carcinoma
por: Shiiya, Haruhiko, et al.
Publicado: (2021)

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
por: Kogure, Yoshihito, et al.
Publicado: (2015)

Radiation-induced sarcoma in a 10-year survivor with stage IV EGFR-mutated lung adenocarcinoma
por: Shibahara, Daisuke, et al.
Publicado: (2019)

Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer
por: Inoue, Tetsuya, et al.
Publicado: (2013)

Notch3 Cooperates With the EGFR Pathway to Modulate Apoptosis Through The Induction Of Bim
por: Konishi, Jun, et al.
Publicado: (2009)

Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage
por: Shoji, Tetsuaki, et al.
Publicado: (2018)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2020)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

Intra‐oesophageal invasion of thymoma
por: Ozawa, Makiko, et al.
Publicado: (2019)

Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
por: Kobayashi, Takashi, et al.
Publicado: (2021)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tk323uddcmmg26la4eirkhb823